JP2016074634A - Oral skin texture improver - Google Patents
Oral skin texture improver Download PDFInfo
- Publication number
- JP2016074634A JP2016074634A JP2014206714A JP2014206714A JP2016074634A JP 2016074634 A JP2016074634 A JP 2016074634A JP 2014206714 A JP2014206714 A JP 2014206714A JP 2014206714 A JP2014206714 A JP 2014206714A JP 2016074634 A JP2016074634 A JP 2016074634A
- Authority
- JP
- Japan
- Prior art keywords
- skin texture
- hyaluronic acid
- skin
- oral
- improving agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000036548 skin texture Effects 0.000 title claims abstract description 50
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 45
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 45
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 45
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 208000017520 skin disease Diseases 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 4
- 229940097043 glucuronic acid Drugs 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- 206010051246 Photodermatosis Diseases 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 230000008845 photoaging Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- FNEHAOQZWPHONV-UHFFFAOYSA-N 9h-carbazole;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C3=CC=CC=C3NC2=C1 FNEHAOQZWPHONV-UHFFFAOYSA-N 0.000 description 2
- UYUXSRADSPPKRZ-UHFFFAOYSA-N D-glucuronic acid gamma-lactone Natural products O=CC(O)C1OC(=O)C(O)C1O UYUXSRADSPPKRZ-UHFFFAOYSA-N 0.000 description 2
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- AEMOLEFTQBMNLQ-QIUUJYRFSA-N beta-D-glucuronic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-QIUUJYRFSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229950002441 glucurolactone Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明は、経口用肌のキメ改善剤に関し、より詳細には、紫外線により誘発される肌のキメの乱れの改善に有効な経口用肌のキメ改善剤に関する。 The present invention relates to an oral skin texture-improving agent, and more particularly to an oral skin texture-improving agent which is effective in improving the disturbance of skin texture induced by ultraviolet rays.
皮膚は常に紫外線に曝露されており、長年かつ繰り返しの紫外線曝露によって皮膚の光老化が促進される。光老化の一つに肌のキメの乱れがある。肌のキメとは、肌の表面にある皮溝と呼ばれる溝に囲まれた三角形や四角形の肌（皮丘）のことであり、「肌のキメが整っている」と言われる肌は、この皮丘が細かく、均一の三角形に整っている状態のことを言う。
肌が紫外線に暴露されると、皮膚の細胞がダメージを受け、正常なターンオーバーが阻害される。そのため、新しい細胞が生まれず肌のキメの乱れにつながると考えられる。肌のキメの乱れは、肌の艶や透明感など見た目の印象に影響するため、肌のキメの乱れを改善する素材や化粧料が強く要望されている。
The skin is constantly exposed to ultraviolet light, and photoaging of the skin is promoted by long-term and repeated exposure to ultraviolet light. One of the photoaging is skin texture disorder. Skin texture refers to triangular or quadrangular skin (cutaneous skin) surrounded by a groove called skin groove on the surface of the skin. A state in which the skin is fine and arranged in a uniform triangle.
When skin is exposed to ultraviolet radiation, skin cells are damaged and normal turnover is impeded. Therefore, it is thought that new cells are not born and the skin texture is disturbed. Since skin texture disturbances affect the appearance of skin, such as gloss and transparency, there is a strong demand for materials and cosmetics that improve skin texture disturbances.
化粧料の成分として広く利用されている原料一つにヒアルロン酸がある。ヒアルロン酸は、生体、特に皮下組織に存在するムコ多糖類であり、高い保湿機能を有している。ヒアルロン酸は、肌のキメの乱れを改善するための化粧料にも利用されており、例えば、ヒアルロン酸、紫外線吸収剤および抗酸化剤を配合した化粧料を皮膚に塗布することにより、日焼け現象等の紫外線障害を抑制することが知られている（特許文献１）。 One raw material widely used as a cosmetic ingredient is hyaluronic acid. Hyaluronic acid is a mucopolysaccharide present in living bodies, particularly subcutaneous tissues, and has a high moisturizing function. Hyaluronic acid is also used in cosmetics to improve skin texture disturbances. For example, by applying cosmetics containing hyaluronic acid, UV absorbers and antioxidants to the skin, the sunburn phenomenon It is known to suppress UV damage such as (Patent Document 1).
しかしながら、従来の化粧料において、ヒアルロン酸は皮膚に潤いを与えるための保湿成分として使用されており、特許文献１の化粧料による紫外線障害の抑制効果も紫外線吸収剤および抗酸化剤により得られるものであるため、ヒアルロン酸のみを皮膚に塗布した場合、紫外線により誘発される肌のキメの乱れを十分に抑制できない問題がある。 However, in conventional cosmetics, hyaluronic acid is used as a moisturizing component for moisturizing the skin, and the effect of suppressing UV damage by the cosmetics of Patent Document 1 can also be obtained by UV absorbers and antioxidants. Therefore, when only hyaluronic acid is applied to the skin, there is a problem that the skin texture disturbance induced by ultraviolet rays cannot be sufficiently suppressed.
さらに、化粧料や外科的処置によって肌のキメの改善が期待できるのは、塗布や処置を行った皮膚の局所的な部分のみであり、広範囲の皮膚で肌のキメの乱れを改善するには不向きである。 Furthermore, the improvement of skin texture can be expected with cosmetics and surgical treatments only in the local area of the skin where the application or treatment has been applied. It is unsuitable.
本発明は、紫外線により誘発された肌のキメの乱れの改善に有効な経口用肌のキメ改善剤を提供する。 The present invention provides an oral skin texture-improving agent that is effective in improving skin texture disturbances induced by ultraviolet rays.
本発明者らは、上記目的を達成すべく鋭意研究を重ねた結果、低分子ヒアルロン酸またはその薬学的に許容される塩が、経口摂取により肌のキメの乱れを改善することを見出し、本発明を完成するに至った。 As a result of intensive studies to achieve the above object, the present inventors have found that low molecular weight hyaluronic acid or a pharmaceutically acceptable salt thereof improves skin texture disorder by ingestion. The invention has been completed.
すなわち、本発明は、
（１）平均分子量１０万以下のヒアルロン酸またはその薬学的に許容される塩を有効成分として含有し、
紫外線による肌のキメの乱れを改善することを特徴とする、
経口用肌のキメ改善剤、
（２）（１）記載の経口用肌のキメ改善剤において、
ヒアルロン酸の平均分子量が１,０００以上３,５００以下である、
経口用肌のキメ改善剤、
である。
That is, the present invention
(1) containing hyaluronic acid having an average molecular weight of 100,000 or less or a pharmaceutically acceptable salt thereof as an active ingredient,
It is characterized by improving skin texture disturbance caused by ultraviolet rays.
Oral skin texture improving agent,
(2) In the oral skin texture improving agent according to (1),
The average molecular weight of hyaluronic acid is 1,000 or more and 3,500 or less,
Oral skin texture improving agent,
It is.
上記経口用肌のキメ改善剤によれば、紫外線により誘発された肌のキメの乱れを改善することができる。 According to the oral skin texture improving agent, it is possible to improve skin texture disturbance induced by ultraviolet rays.
また、上記経口用肌のキメ改善剤は経口摂取するものであることから、生体内で作用することができるため、広範囲の皮膚で光老化を抑制することができる。 In addition, since the above-mentioned oral skin texture improving agent is taken orally, it can act in vivo, so that photoaging can be suppressed in a wide range of skins.
以下、図面を参照しつつ、本発明を詳細に説明する。なお、本発明において、格別に断らない限り、「％」は「質量％」を意味する。 Hereinafter, the present invention will be described in detail with reference to the drawings. In the present invention, “%” means “mass%” unless otherwise specified.
＜本発明の特徴＞
本発明の経口用肌のキメ改善剤は、平均分子量１０万以下のヒアルロン酸またはその薬学的に許容される塩を有効成分として含有することより紫外線による肌のキメの乱れを改善することを特徴とする。
<Features of the present invention>
The oral skin texture improving agent of the present invention comprises hyaluronic acid having an average molecular weight of 100,000 or less or a pharmaceutically acceptable salt thereof as an active ingredient, thereby improving skin texture disturbance due to ultraviolet rays. And
＜ヒアルロン酸またはその薬学的に許容される塩＞
本発明において、「ヒアルロン酸」とは、β−Ｄ−グルクロン酸とβ−Ｄ−Ｎ−アセチルグルコサミンとの二糖からなる繰り返し構成単位を１以上有する多糖類である。すなわち、ヒアルロン酸は、β−Ｄ−グルクロン酸の１位とβ−Ｄ−Ｎ−アセチル−グルコサミンの３位とが結合した２糖単位を少なくとも１個含む２糖以上のものである。また、「ヒアルロン酸の薬学的に許容される塩」としては、特に限定されないが、例えば、ナトリウム塩、カリウム塩、カルシウム塩、亜鉛塩、マグネシウム塩、アンモニウム塩等が挙げられる。
<Hyaluronic acid or a pharmaceutically acceptable salt thereof>
In the present invention, “hyaluronic acid” is a polysaccharide having one or more repeating structural units composed of disaccharides of β-D-glucuronic acid and β-DN-acetylglucosamine. That is, hyaluronic acid is a disaccharide or more containing at least one disaccharide unit in which the 1-position of β-D-glucuronic acid and the 3-position of β-DN-acetyl-glucosamine are bonded. The “pharmaceutically acceptable salt of hyaluronic acid” is not particularly limited, and examples thereof include sodium salt, potassium salt, calcium salt, zinc salt, magnesium salt, ammonium salt and the like.
＜ヒアルロン酸またはその薬学的に許容される塩の由来＞
ヒアルロン酸またはその薬学的に許容される塩は、動物等の生体組織（例えば鶏冠、さい帯、皮膚、関節液等）から抽出されたものでもよく、あるいは、微生物、動物細胞または植物細胞を培養して得られたもの（例えばストレプトコッカス属の細菌等を用いた発酵法）、化学的または酵素的に合成されたもの等を使用することができる。
<Origin of hyaluronic acid or a pharmaceutically acceptable salt thereof>
Hyaluronic acid or a pharmaceutically acceptable salt thereof may be extracted from a living tissue such as an animal (for example, chicken crown, umbilical cord, skin, joint fluid, etc.), or cultured microorganisms, animal cells or plant cells. (Eg, a fermentation method using Streptococcus bacteria), chemically or enzymatically synthesized products, and the like can be used.
＜ヒアルロン酸またはその薬学的に許容される塩の純度＞
なお、本発明において使用するヒアルロン酸またはその薬学的に許容される塩の純度は、医薬品で使用できるレベルであればよく、具体的には９０％以上であればよく、さらに９５％以上であればよい。この純度は、カルバゾール硫酸法（例えば日本薬局方）にて測定されたグルクロン酸定量値から算出された値である。
<Purity of hyaluronic acid or a pharmaceutically acceptable salt thereof>
The purity of hyaluronic acid or a pharmaceutically acceptable salt thereof used in the present invention may be a level that can be used in pharmaceuticals, specifically 90% or more, and more than 95%. That's fine. This purity is a value calculated from a glucuronic acid quantitative value measured by a carbazole sulfate method (for example, Japanese Pharmacopoeia).
カルバゾール硫酸法は、ホウ酸ナトリウム・硫酸溶液中にヒアルロン酸水溶液を加えて混和し、ヒアルロン酸を加熱分解した後冷却し、カルバゾール・エタノール溶液を加えて混和し、加熱後放冷した試料液の吸光度（５３０ｎｍ）を測定する方法である。同様に処理したＤ−グルクロノラクトンを用いて検量線を作成し、Ｄ−グルクロノラクトン換算値を算出した後、１．１０２を乗じてグルクロン酸定量値を求める。得られたグルクロン酸定量値に（ヒアルロン酸の分子量／グルクロン酸の分子量）を乗じてヒアルロン酸の含有量を算出する。 In the carbazole sulfate method, an aqueous solution of hyaluronic acid is added and mixed in a sodium borate / sulfuric acid solution, the hyaluronic acid is decomposed by heating, cooled, mixed with a carbazole / ethanol solution, heated and left to cool. This is a method for measuring absorbance (530 nm). A calibration curve is prepared using D-glucuronolactone processed in the same manner, and a D-glucuronolactone conversion value is calculated, and then multiplied by 1.102 to obtain a glucuronic acid quantitative value. The obtained glucuronic acid quantitative value is multiplied by (molecular weight of hyaluronic acid / molecular weight of glucuronic acid) to calculate the content of hyaluronic acid.
＜ヒアルロン酸またはその薬学的に許容される塩の平均分子量＞
また、本発明の経口用肌のキメ改善剤で使用するヒアルロン酸またはその薬学的に許容される塩の平均分子量は、１０万以下であり、肌のキメ改善効果を十分に得られる点から、１万以下であればよく、さらに４００以上５,０００以下、１，０００以上３，５００以下であればよい。
<Average molecular weight of hyaluronic acid or a pharmaceutically acceptable salt thereof>
In addition, the average molecular weight of hyaluronic acid or a pharmaceutically acceptable salt thereof used in the oral skin texture improving agent of the present invention is 100,000 or less, from the point that a skin texture improving effect can be sufficiently obtained. It may be 10,000 or less, and may be 400 or more and 5,000 or less, or 1,000 or more and 3,500 or less.
経口摂取されたヒアルロン酸が、紫外線により誘発される肌のキメの乱れを改善するメカニズムについては必ずしも明らかではないが、紫外線による表皮細胞のターンオーバー阻害を抑制することで、肌のキメの乱れを改善すると考えられる。ヒアルロン酸の平均分子量が１０万よりも大きいと、肌のキメの乱れを改善する効果を得ることができない。
なお、本発明で規定されるヒアルロン酸またはその薬学的に許容される塩の平均分子量は、常法に則り、極限粘度法やＨＰＬＣ法等で測定することができる。
The mechanism by which hyaluronic acid taken orally improves the skin texture disturbance induced by ultraviolet rays is not necessarily clear, but by suppressing the inhibition of epidermal cell turnover by ultraviolet rays, the skin texture disturbance is suppressed. It is thought to improve. When the average molecular weight of hyaluronic acid is greater than 100,000, it is not possible to obtain the effect of improving skin texture disturbance.
The average molecular weight of hyaluronic acid or a pharmaceutically acceptable salt thereof defined in the present invention can be measured by an intrinsic viscosity method, an HPLC method or the like according to a conventional method.
＜ヒアルロン酸またはその薬学的に許容される塩の含有量＞
本発明の経口用肌のキメ改善剤におけるヒアルロン酸またはその薬学的に許容される塩の含有量は、ヒアルロン酸またはその薬学的に許容される塩が有効成分として機能しうる量であればよく、具体的には０．１質量％以上であればよく、さらに１％以上１００質量％以下であればよい。
<Content of hyaluronic acid or a pharmaceutically acceptable salt thereof>
The content of hyaluronic acid or a pharmaceutically acceptable salt thereof in the texture improving agent for oral skin of the present invention may be an amount that allows hyaluronic acid or a pharmaceutically acceptable salt thereof to function as an active ingredient. Specifically, it may be 0.1% by mass or more, and may be 1% or more and 100% by mass or less.
＜経口用肌のキメ改善剤の肌のキメ改善効果の確認方法＞
本発明の経口用肌のキメ改善剤の、肌のキメの乱れを改善する効果は、例えば、背部の肌のキメをマイクロスコープやビジオスキャン等で撮影し、肌のキメの状態を確認することで評価することができる。
<Method for Confirming Skin Texture Improvement Effect of Oral Skin Texture Improvement Agent>
The effect of improving the texture of the skin texture of the oral skin texture improving agent of the present invention is, for example, photographing the texture of the back skin with a microscope or Vizioscan to confirm the condition of the skin texture. Can be evaluated.
＜経口用肌のキメ改善剤に用いる他の原料＞
本発明の経口用肌のキメ改善剤は、有効成分であるヒアルロン酸またはその薬学的に許容される塩以外に、本発明の効果を損なわない範囲で、その他の原料を含むことができる。そのような原料の例としては水、賦形剤、抗酸化剤、防腐剤、湿潤剤、粘稠剤、緩衝剤、吸着剤、溶剤、乳化剤、安定化剤、界面活性剤、滑沢剤、水溶性高分子、甘味料、矯味剤、酸味料、アルコール類等が挙げられる。
<Other raw materials used as a texture improving agent for oral skin>
In addition to hyaluronic acid or a pharmaceutically acceptable salt thereof as an active ingredient, the oral skin texture improving agent of the present invention can contain other raw materials as long as the effects of the present invention are not impaired. Examples of such raw materials are water, excipients, antioxidants, preservatives, wetting agents, thickeners, buffers, adsorbents, solvents, emulsifiers, stabilizers, surfactants, lubricants, Water-soluble polymers, sweeteners, flavoring agents, acidulants, alcohols and the like can be mentioned.
＜経口用肌のキメ改善剤の剤形＞
本発明の経口用肌のキメ改善剤の剤形は特に限定されないが、本発明の経口用肌のキメ改善剤を経口摂取する場合、例えば錠剤、散剤、細粒剤、顆粒剤、カプセル剤、丸剤等の固形製剤、水剤、懸濁剤、シロップ剤、乳剤等の液剤等の経口投与剤が挙げられる。
<Form of oral skin texture improving agent>
The dosage form of the oral skin texture improving agent of the present invention is not particularly limited, but when the oral skin texture improving agent of the present invention is orally ingested, for example, tablets, powders, fine granules, granules, capsules, Examples include oral preparations such as solid preparations such as pills, liquid preparations such as liquids, suspensions, syrups, and emulsions.
＜経口用肌のキメ改善剤の摂取量＞
ヒアルロン酸またはその薬学的に許容される塩は生体物質であるため、多量に摂取しても副作用がない、またはきわめて低いと考えられるが、本発明の経口用肌のキメ改善剤として摂取するヒアルロン酸及び／またはその塩の量は、一日当たり１０ｍｇ以上１０００ｍｇ以下、さらに１００ｍｇ以上５００ｍｇ以下を目安とすることができる。投与回数は、紫外線照射量や季節に応じて一日当たり一回もしくは複数回を選択できる。
<Intake of oral skin texture improver>
Hyaluronic acid or a pharmaceutically acceptable salt thereof is a biological substance, and therefore, it is considered that there is no side effect or extremely low even when ingested in large amounts. The amount of the acid and / or salt thereof may be 10 mg to 1000 mg, more preferably 100 mg to 500 mg per day. The number of administrations can be selected once or a plurality of times per day depending on the ultraviolet irradiation amount and the season.
以下、実施例によって本発明をさらに詳細に説明するが、本発明は実施例に限定されない。 EXAMPLES Hereinafter, although an Example demonstrates this invention further in detail, this invention is not limited to an Example.
＜実施例１＞
平均分子量２,０００のヒアルロン酸（白色粉末、キユーピー株式会社製：純度９９％）を精製水に溶解させ、実施例１の経口用肌のキメ改善剤を得た。なお、後述する試験例において、ヒアルロン酸の投与量が４００ｍｇ／ｋｇ／日となるように、マウスの平均体重及び平均飲水量から濃度を算出して、試験液を調製した。実施例１の経口用肌のキメ改善剤に含まれるヒアルロン酸の濃度は、０．１％以上であった。
<Example 1>
Hyaluronic acid having an average molecular weight of 2,000 (white powder, manufactured by QP Corporation: purity 99%) was dissolved in purified water to obtain a texture improving agent for oral skin of Example 1. In the test examples to be described later, the test solution was prepared by calculating the concentration from the average body weight and the average water intake of the mice so that the dose of hyaluronic acid was 400 mg / kg / day. The concentration of hyaluronic acid contained in the texture improving agent for oral skin of Example 1 was 0.1% or more.
＜試験例＞
ヒアルロン酸の肌のキメ改善作用を確認するため、へアレスマウスを用いた試験を行った。
<Test example>
In order to confirm the skin texture-improving effect of hyaluronic acid, a test using hairless mice was performed.
Ｈｏｓ：ＨＲ−１系雄マウス（６週齢）を体重に有意差のないよう群分けを行った後、実施例１の試験液及び精製水を７日間投与した。投与７日後に、マウスの背部皮膚にＵＶＢを照射し（１００ｍＪ／ｃｍ２）、肌のキメの乱れを誘発した。ＵＶＢ照射後、さらに３日間実施例１の試験液又は精製水を投与し、その後マウス背部の写真をビジオスキャン（Ｖｉｓｉｏｓｃａｎ ＶＣ９８ＵＳＢ、株式会社インテグラル製）で撮影した。対照として、精製水を投与し、かつＵＶＢ照射を行わなかったマウスの背部写真も同様に撮影した。なお、１日あたりのヒアルロン酸の投与量は、１０ｍｇ以上であった。 After grouping Hos: HR-1 male mice (6 weeks old) so that there was no significant difference in body weight, the test solution and purified water of Example 1 were administered for 7 days. Seven days after administration, the back skin of the mice was irradiated with UVB (100 mJ / cm 2 ) to induce skin texture disturbance. After UVB irradiation, the test solution or purified water of Example 1 was further administered for 3 days, and then a photograph of the back of the mouse was taken with Vizioscan (Visioscan VC98USB, manufactured by Integral). As a control, a photograph of the back of a mouse administered with purified water and not irradiated with UVB was also taken. The dose of hyaluronic acid per day was 10 mg or more.
＜背部皮膚の写真＞
背部皮膚の写真を図１に示した。
図１より、精製水を投与したマウスは肌のキメが大きく、形が不規則であり、肌のキメが乱れた状態になっていたが、実施例１の試験液を投与したマウスは、精製水を投与したマウスよりも肌のキメが細かく、乱れが改善されていた。
この結果より、ヒアルロン酸を経口投与することにより、紫外線により誘発される肌のキメの乱れを改善できることが分かった。
<Photo of back skin>
A photograph of the back skin is shown in FIG.
From FIG. 1, the mouse administered with purified water had large skin texture, irregular shape, and disordered skin texture, but the mouse administered with the test solution of Example 1 was purified. The skin texture was finer than that of the mice to which water was administered, and the disturbance was improved.
From this result, it has been found that the skin texture disturbance induced by ultraviolet rays can be improved by orally administering hyaluronic acid.
＜実施例２＞
実施例１で使用したヒアルロン酸を使用して、下記の配合の経口用肌のキメ改善剤(顆粒剤）を製した。
<Example 2>
Using the hyaluronic acid used in Example 1, an oral skin texture improving agent (granule) having the following composition was prepared.
［配合割合］
ヒアルロン酸（平均分子量２，０００） １０％
乳糖 ６０％
トウモロコシデンプン ２５％
ヒプロメロース ５％
――――――――――――――――――――――――――――――――
１００％
[Combination ratio]
Hyaluronic acid (average molecular weight 2,000) 10%
Lactose 60%
Corn starch 25%
Hypromellose 5%
――――――――――――――――――――――――――――――――
100%
＜実施例３＞
実施例１で使用したヒアルロン酸を使用して、下記の配合の経口用肌のキメ改善剤（ソフトカプセル）を製した。
<Example 3>
Using the hyaluronic acid used in Example 1, an oral skin texture improving agent (soft capsule) having the following composition was prepared.
［配合割合］
ヒアルロン酸（平均分子量２，０００） ２０％
オリーブ油 ５０％
ミツロウ １０％
中鎖脂肪酸トリグリセリド １０％
乳化剤 １０％
――――――――――――――――――――――――――――――――
１００％
[Combination ratio]
Hyaluronic acid (average molecular weight 2,000) 20%
50% olive oil
Beeswax 10%
Medium chain fatty acid triglyceride 10%
Emulsifier 10%
――――――――――――――――――――――――――――――――
100%
Claims (2)
紫外線による肌のキメの乱れを改善することを特徴とする、
経口用肌のキメ改善剤。 Containing hyaluronic acid having an average molecular weight of 100,000 or less or a pharmaceutically acceptable salt thereof as an active ingredient,
It is characterized by improving skin texture disturbance caused by ultraviolet rays.
Oral skin texture improving agent.
ヒアルロン酸の平均分子量が１,０００以上３,５００以下である、
経口用肌のキメ改善剤。 In the oral skin texture improving agent according to claim 1,
The average molecular weight of hyaluronic acid is 1,000 or more and 3,500 or less,
Oral skin texture improving agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014206714A JP2016074634A (en) | 2014-10-07 | 2014-10-07 | Oral skin texture improver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014206714A JP2016074634A (en) | 2014-10-07 | 2014-10-07 | Oral skin texture improver |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2016074634A true JP2016074634A (en) | 2016-05-12 |
Family
ID=55949633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014206714A Pending JP2016074634A (en) | 2014-10-07 | 2014-10-07 | Oral skin texture improver |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2016074634A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009051877A (en) * | 2007-08-23 | 2009-03-12 | Q P Corp | New hyaluronic acid and/or salt thereof, food composition and oral medicinal composition using the same, and oral skin ameliorating agent or oral skin water content-increasing agent comprising the hyaluronic acid and/or the salt thereof as active ingredient |
| JP2011173810A (en) * | 2010-02-23 | 2011-09-08 | Mikimoto Pharmaceut Co Ltd | Method for producing cosmetic |
| WO2011129374A1 (en) * | 2010-04-14 | 2011-10-20 | ロート製薬株式会社 | Composition for external use for complexion improvement |
-
2014
- 2014-10-07 JP JP2014206714A patent/JP2016074634A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009051877A (en) * | 2007-08-23 | 2009-03-12 | Q P Corp | New hyaluronic acid and/or salt thereof, food composition and oral medicinal composition using the same, and oral skin ameliorating agent or oral skin water content-increasing agent comprising the hyaluronic acid and/or the salt thereof as active ingredient |
| JP2011173810A (en) * | 2010-02-23 | 2011-09-08 | Mikimoto Pharmaceut Co Ltd | Method for producing cosmetic |
| WO2011129374A1 (en) * | 2010-04-14 | 2011-10-20 | ロート製薬株式会社 | Composition for external use for complexion improvement |
Non-Patent Citations (4)
| Title |
|---|
| BIOSCI. BIOTECHNOL. BIOCHEM., vol. 72, no. 4, JPN6017000021, 2008, pages 1111 - 1114, ISSN: 0003833640 * |
| FANCL HEALTH SCIENCE 報道関係者各位（新製品情報）, vol. [平成２９年１２月２０日検索], JPN6017050059, April 2014 (2014-04-01), ISSN: 0003833637 * |
| FANCL HEALTH SCIENCE報道関係者各位（新製品情報）, vol. [平成２９年１２月２０日検索], JPN6017050060, 2011, ISSN: 0003833638 * |
| 川田 千夏 CHINATSU KAWADA: "ＵＶ照射ヘアレスマウスへのヒアルロン酸投与による皮膚状態改善効果 Oral Intake of Hyaluronic Acid imp", 日本農芸化学会大会講演要旨集（ＣＤ−ＲＯＭ）, JPN6017000020, 2012, pages 398, ISSN: 0003833639 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5876962B2 (en) | Composition for external use | |
| CN1110302C (en) | Oxa acids and related compounds for treating skin conditions | |
| JP5951173B2 (en) | Method for inhibiting discoloration of composition for external use containing diphenhydramine or salt thereof and ascorbic acid or salt thereof | |
| JPWO2004085429A1 (en) | Composition for promoting type I collagen and / or elastin production | |
| JP5891651B2 (en) | Skin preparation for normalization of stratum corneum cell differentiation | |
| JP5102944B2 (en) | Topical skin preparation | |
| JP6026717B2 (en) | Hyaluronic acid production promoter | |
| JP2010222313A (en) | Hyaluronic acid production promoter | |
| JP6437148B2 (en) | Composition for external use | |
| JP2016074634A (en) | Oral skin texture improver | |
| JP2007186439A (en) | Skin care preparation | |
| JP2011195534A (en) | Hyaluronic acid production promoter, anti-ageing agent and wrinkle-ameliorating agent | |
| WO2012008457A1 (en) | Composition for external application | |
| JP4993890B2 (en) | Topical skin preparation | |
| JP6185773B2 (en) | Pharmaceutical composition | |
| JP2010260808A (en) | Oral medicinal composition for improving skin condition | |
| WO2016002840A1 (en) | Transparent aqueous topical formulation | |
| JP2006219450A (en) | Skin care preparation | |
| JP7396585B2 (en) | Composition for suppressing TSLP gene expression, suppressing IL-33 gene expression, or promoting filaggrin production | |
| JP2005112762A (en) | Skin care preparation for external use | |
| JP6266546B2 (en) | Cartilage protection and joint protection | |
| JP6608620B2 (en) | Topical skin preparation | |
| JP2013032407A (en) | Composition for treating or preventing arthralgia | |
| JP2017190346A (en) | Pharmaceutical composition | |
| JP2004107238A (en) | Kit for improving dry skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170427 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180109 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180710 |